All posts tagged: Drug Development

In CAC2's June webinar, "Beyond the Signature: Demystifying Informed Consent in Childhood Cancer," we brought together an extraordinary panel of experts, including a clinical ethicist, a pediatric oncologist, and a parent advocate, who each offered unique and deeply informed perspectives on how we can make this informed consent process more ethical, transparent, and truly family-centered. Informed consent is more than just a signature on a form.  It is a vital process that ensures families understand, trust, and feel empowered in the face of one of the hardest decisions they may ever make: enrolling their child in a clinical trial. In [...] Read more

In CAC2's May webinar, "Fertility Hope for Childhood Cancer Survivors" our speakers explored fertility preservation and future family building options for childhood cancer patients and survivors. Dr. Leena Nahata (Nationwide Children’s Hospital) spoke first and covered a range of topics including How and when to have fertility preservation conversations Risk stratification overview Ovarian tissue cryopreservation Testicular tissue cryopreservation Egg and sperm banking Long term storage Megan Scherer (Worth the Wait) and CAC2 Member Nick Giallourakis (Elephants and Tea) followed and provided real world stories concerning helping survivors with fertility preservation and family building, the importance of providing stories of hope [...] Read more

In CAC2's April pop-up webinar, "Patient Advocacy, Non-Profit Foundations, and the Changing Landscape of Pediatric Cancer Funding," our special guest, Dr. Kimryn Rathmell, shared compelling insights on the evolving pediatric cancer landscape and the role of advocates. Dr. Rathmell recently completed her appointment as the 17th Director of the National Cancer Institute and has taken a new role as CEO of the Ohio State James Cancer Hospital and Solve Research Institute. Her presentation drew from a distinguished career of scientific excellence and compassionate leadership that spanned from her acclaimed work in kidney cancer genomics to her vision for the future [...] Read more

In CAC2's April webinar, "The Role of AI from Diagnosis to Treatment for Childhood Cancer," our speakers explored how Artificial Intelligence is being used in pediatric cancer and how to harness the full potential on behalf of patients by enhancing diagnosis, treatment planning, and patient outcomes. Dr. Resnick spoke first and articulated how Artificial Intelligence (AI) will play a transformative role in pediatric cancer research by enhancing diagnosis, treatment planning, and patient outcomes. AI is being used to analyze complex datasets, improve the speed, provide new diagnostic capabilities, accuracy, and personalize treatment strategies, thereby creating new opportunities for children with [...] Read more

In CAC2's "Fit for Filing" webinar, our speakers explored designing and conducting academic or academic industry collaborative trials that produce data suitable for regulatory filing. This presentation covered best practices and considerations for conducting trials ready to submit for regulatory approval. The panel examined multiple perspectives, including academia, industry, regulatory authorities, funding organizations, and patient advocates. The speakers emphasized the importance of early, robust, and multi-directional partnerships among academic investigators, cooperative groups, regulatory agencies, and industry, and how funding organizations can help promote these collaborations that are crucial to ensure the unmet medical needs of children with cancer remains a [...] Read more